🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Multiple Sclerosis (MS)

MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis NCT07444047n/a1 site📍 Oslo Oslo University Hospital Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis NCT05633875n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: MRI Home Based Functional Balance Intervention for Multiple Sclerosis NCT07355387NA1 site📍 Chicago University of Illinois at Chicago · Tests: Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibul… Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers NCT05395624Phase 1, Phase 23 sites📍 San Francisco📍 Stanford📍 Jacksonville Ashvattha Therapeutics, Inc. · Tests: 18F-OP-801 Impact of TTNS on Bladder Symptoms Among People With MS, A RCT NCT06341673NA1 site📍 Khobar Hawra Al-Dandan · Tests: Active Transcutaneous Electrical Nerve Stimulation (TENS), Sham Transcutaneous Electrical Nerve Stimulation (TENS) MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis NCT05491031NA1 site📍 Poitiers Poitiers University Hospital · Tests: magnetic resonance spectroscopy A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) NCT06780150n/a93 sites📍 Aachen📍 Amberg📍 Arnsdorf Hoffmann-La Roche · Tests: Ocrelizumab Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. NCT06280755n/a3 sites📍 Prague📍 Bochum📍 Berlin icometrix Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) NCT06901687Phase 21 site📍 New York NYU Langone Health · Tests: Active tDCS, Sham tDCS Fatigue and Mental Well-Being in MS Patients(Multiple Sclerosis) NCT07544303NA1 site📍 Van Artvin Coruh University · Tests: Quran recital A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) NCT06433765n/a1 site📍 Wilmington TG Therapeutics, Inc. · Tests: No intervention Cognitive-motor Telerehabilitation in MS NCT05355389NA2 sites📍 Brussels📍 Melsbroek Universitair Ziekenhuis Brussel · Tests: Cognitive training, Motor training Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis NCT07497399Phase 22 sites📍 Baltimore📍 New York Johns Hopkins University · Tests: NLY01, Placebo Body Awareness, Trunk Stability, and Arm Function in MS NCT07151534n/a1 site📍 Ankara Hacettepe University Molecular Imaging of NET Using [C-11]MRB-PET in MS NCT03207464Phase 1, Phase 21 site📍 Boston Brigham and Women's Hospital · Tests: [C-11]Methylreboxetine ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS NCT06733922Phase 414 sites📍 Calgary📍 Calgary📍 Edmonton Novartis Pharmaceuticals · Tests: ETNATM-ProgMS At Home Use of Stimulation Suits for Managing MS Symptoms NCT07202195NA2 sites📍 Steenokkerzeel📍 Ry Daphne Kos · Tests: electro-stimulation suit, Usual Care Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. NCT06846281Phase 3131 sites📍 Scottsdale📍 Irvine📍 Washington D.C. Novartis Pharmaceuticals · Tests: Remibrutinib oral treatment, Ocrelizumab Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research NCT07623668Phase 34 sites📍 Livonia📍 Charleston📍 Dallas Oculis · Tests: Privosegtor, Methylprednisolone, Placebo Vancomycin Study in Multiple Sclerosis (MS) NCT05539729Phase 11 site📍 New York Icahn School of Medicine at Mount Sinai · Tests: Vancomycin, Placebo Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis NCT07477639Phase 1, Phase 28 sites📍 La Jolla📍 Kansas City📍 Rochester Tr1X, Inc. · Tests: TRX319, Bendamustine Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND) NCT07360977NA1 site📍 Messina IRCCS Centro Neurolesi Bonino Pulejo · Tests: bioactivated GRA for adult patients, bioactivated GRA for pediatric patients Exploring the Utility of [18F]3F4AP for Demyelination Imaging NCT06999434Phase 11 site📍 New Haven Yale University · Tests: [ 18F]3F4AP, [18F]MK6240, [11C]PIB Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent NCT04933552n/a1 site📍 La Jolla Novartis Pharmaceuticals · Tests: Siponimod Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands NCT06567197n/a2 sites📍 Amsterdam📍 Nieuwegein Amsterdam UMC, location VUmc Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis NCT07389590Phase 41 site📍 Baltimore Johns Hopkins University · Tests: Ublituximab, Ocrelizumab Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628Phase 323 sites📍 Palo Alto📍 Aurora📍 Evanston National Institute of Allergy and Infectious Diseases (NIAI… · Tests: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis NCT07318129NA1 site📍 Glostrup Municipality Glostrup University Hospital, Copenhagen · Tests: Placebo, Indole-3-propionic acid (IPA) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients NCT07085507Phase 1, Phase 21 site📍 Adelaide Vidya Therapeutics Inc · Tests: VT7208, Placebo Adverse Childhood Experiences in Patients With MS: Impact on Quality of Life and on Coping Strategies Towards the Disease and Its Treatment NCT06718920n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy